Log in or Sign up for Free to view tailored content for your specialty!
Steatohepatitis/Metabolic Liver Disease News
Pemvidutide linked to ‘rapid and potent’ reduction in liver fat in MASLD at 12 weeks
Pemvidutide, a glucagon-like peptide-1/glucagon dual receptor agonist, lowered liver fat content, markers of inflammation and body weight in patients with metabolic dysfunction-associated steatotic liver disease and obesity, research showed.
Model may ‘serve as a starting point’ to identify patients with MASLD at high risk for HCC
A prediction model could be a “starting point” to identify patients with metabolic dysfunction-associated steatotic liver disease at high risk for hepatocellular carcinoma who may require intervention or surveillance, researchers wrote.
Log in or Sign up for Free to view tailored content for your specialty!
VIDEO: GLP-1 use for MASH is ‘not black and white’; best approach may lie in the gray
In a Healio video exclusive, Edward V. Loftus Jr., MD, noted that, despite the boom in glucagon-like peptide-1 agonists for diabetes and weight loss, its role in the treatment of liver disease is still up for debate.
‘Highly plausible’ GLP-1s can improve health-related QoL, economic burden of MASH
Metabolic dysfunction-associated steatotic liver disease affects more than one-third of the world’s population and is associated with significant clinical and economic burden, as well as impairment of health-related quality of life.
‘Whether or not we like it,’ GLP-1s are part of hepatology, treatment of MASH
To put it simply, diabetes and steatotic liver disease are joined at the hip. They are part of the same biological process that involves multiple organs, connected by the concept of metabolic flexibility — or lack thereof.
More data needed on GLP-1s, dual agonists to reach ‘optimal’ management of MASH, diabetes
Metabolic dysfunction-associated steatohepatitis is significantly more common in patients with type 2 diabetes, and most patients with MASH — formerly known as NASH — experience metabolic abnormalities, including obesity.
‘Future of treating MASH’ will combine GLP-1 drugs, liver-specific medications
Metabolic dysfunction-associated steatotic liver disease is a public health threat, affecting 30% to 38% of the adult population globally. The prevalence has risen in parallel with epidemics of obesity and type 2 diabetes.
Manage lifestyle early and aggressively to prevent, instead of treat, fatty liver
Millions of dollars have been spent trying to find medications that could treat this complex disorder. The focus has been on drugs for more severe disease, as it leads to complications, and early stages have been somewhat ignored.
‘Unequivocally yes’: MASH therapies still needed despite boom in GLP-1 use in liver disease
Although use of glucagon-like peptide-1 agonists for diabetes and weight loss has soared with indications now expanding into liver diseases, specifically metabolic dysfunction-associated steatohepatitis, the jury is still out on its benefit.
Nearly 62% achieve MASH resolution without worsening of fibrosis with tirzepatide
Patients with metabolic dysfunction-associated steatohepatitis and advanced fibrosis treated with tirzepatide achieved significant disease resolution without worsening of fibrosis, compared with those on placebo, according to research.
-
Headline News
Rise in alcohol use during pandemic endures as 'an alarming public health issue'
November 14, 20242 min read -
Headline News
AI identified patient messages sent by proxies, but also broke confidentiality
November 14, 20242 min read -
Headline News
Diabetes inequities persist worldwide, especially for low-, middle-income countries
November 14, 20243 min read
-
Headline News
Rise in alcohol use during pandemic endures as 'an alarming public health issue'
November 14, 20242 min read -
Headline News
AI identified patient messages sent by proxies, but also broke confidentiality
November 14, 20242 min read -
Headline News
Diabetes inequities persist worldwide, especially for low-, middle-income countries
November 14, 20243 min read